PURPOSE: We conducted a phase I and pharmacologic study of a weekly 96-hour infusion of irinotecan to determine the maximum-tolerated dose, define the toxicity profile, and characterize the clinical pharmacology of irinotecan and its metabolites. PATIENTS AND METHODS: In 26 adult patients with solid tumors, the duration and dose rate of infusion were escalated in new patients until toxicity was observed. RESULTS: In 11 patients who were treated with irinotecan at 12.5 mg/m(2)/d for 4 days weekly for 2 of 3 weeks, dose-limiting grade 3 diarrhea occurred in three patients and grade 3 thrombocytopenia occurred in two patients. The recommended phase II dose is 10 mg/m(2)/d for 4 days given weekly for 2 of 3 weeks. At this dose, the steady-state plasma concentration (Css) of total SN-38 (the active metabolite of irinotecan) was 6.42 +/- 1.10 nmol/L, and the Css of total irinotecan was 28.60 +/- 17.78 nmol/L. No patient experienced grade 3 or 4 neutropenia during any cycle. All other toxicities were mild to moderate. The systemic exposure to SN-38 relative to irinotecan was greater than anticipated, with a molar ratio of the area under the concentration curve (AUC) of SN-38 to irinotecan of 0.24 +/- 0.08. One objective response lasting 12 months in duration was observed in a patient with metastatic colon cancer. CONCLUSION: The recommended phase II dose of irinotecan of 10 mg/m(2)/d for 4 days weekly for 2 of 3 weeks was extremely well tolerated. Further efficacy testing of this pharmacologic strategy of administering intermittent low doses of irinotecan is warranted.
PURPOSE: We conducted a phase I and pharmacologic study of a weekly 96-hour infusion of irinotecan to determine the maximum-tolerated dose, define the toxicity profile, and characterize the clinical pharmacology of irinotecan and its metabolites. PATIENTS AND METHODS: In 26 adult patients with solid tumors, the duration and dose rate of infusion were escalated in new patients until toxicity was observed. RESULTS: In 11 patients who were treated with irinotecan at 12.5 mg/m(2)/d for 4 days weekly for 2 of 3 weeks, dose-limiting grade 3 diarrhea occurred in three patients and grade 3 thrombocytopenia occurred in two patients. The recommended phase II dose is 10 mg/m(2)/d for 4 days given weekly for 2 of 3 weeks. At this dose, the steady-state plasma concentration (Css) of total SN-38 (the active metabolite of irinotecan) was 6.42 +/- 1.10 nmol/L, and the Css of total irinotecan was 28.60 +/- 17.78 nmol/L. No patient experienced grade 3 or 4 neutropenia during any cycle. All other toxicities were mild to moderate. The systemic exposure to SN-38 relative to irinotecan was greater than anticipated, with a molar ratio of the area under the concentration curve (AUC) of SN-38 to irinotecan of 0.24 +/- 0.08. One objective response lasting 12 months in duration was observed in a patient with metastatic colon cancer. CONCLUSION: The recommended phase II dose of irinotecan of 10 mg/m(2)/d for 4 days weekly for 2 of 3 weeks was extremely well tolerated. Further efficacy testing of this pharmacologic strategy of administering intermittent low doses of irinotecan is warranted.
Authors: Moritz N Wente; Jörg Kleeff; Markus W Büchler; Jantien Wanders; Peter Cheverton; Stephen Langman; Helmut Friess Journal: Invest New Drugs Date: 2005-08 Impact factor: 3.850
Authors: Heinz-Josef Lenz; Philip Philip; Mark Saunders; Tatjana Kolevska; Kalyan Mukherjee; Leslie Samuel; Shailesh Bondarde; Tracy Dobbs; Mary Tagliaferri; Ute Hoch; Alison L Hannah; Maurice Berkowitz Journal: Cancer Chemother Pharmacol Date: 2017-10-17 Impact factor: 3.333
Authors: B Melichar; E Casado; J Bridgewater; J Bennouna; M Campone; P Vitek; J-P Delord; J Cerman; R Salazar; J Dvorak; C Sguotti; P Urban; K Viraswami-Appanna; E Tan; J Tabernero Journal: Br J Cancer Date: 2011-10-25 Impact factor: 7.640
Authors: N E Schoemaker; I E L M Kuppens; V Moiseyenko; B Glimelius; M Kjaer; H Starkhammer; D J Richel; R Smaaland; K Bertelsen; J P Poulsen; E Voznyi; J Norum; D Fennelly; K M Tveit; A Garin; G Gruia; A Mourier; D Sibaud; P Lefebvre; J H Beijnen; J H M Schellens; W W ten Bokkel Huinink Journal: Br J Cancer Date: 2004-10-18 Impact factor: 7.640
Authors: Javier Cortés; Hope S Rugo; Chris Twelves; Ahmad Awada; Edith A Perez; Seock-Ah Im; Carol Zhao; Ute Hoch; Denise Tomkinson; James Buchanan; Mary Tagliaferri; Alison Hannah; Joyce O'Shaughnessy Journal: Springerplus Date: 2016-07-08